Armed with an old drug and new data, the group is aiming to revitalize the smoking cessation market. 

Cytokinetics has a lot riding on the upcoming Phase III readout for aficamten, and crunch time is coming for plenty of other groups, too. 

A positive showing by Bristol Myers Squibb’s checkpoint inhibitor Opdivo in non-small cell lung cancer could broaden its use, though much depends on the magnitude of the hit.

The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.

Despite the astounding efficacy and commercial potential of incretins in obesity, many groups are trying different mechanistic approaches to the disease – if only to enable combinations. 

A catastrophic late-stage clinical failure wipes 60% off the group’s value – and boosts a rival.